Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel P Rossignol

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Anesthesia and Analgesia|January 24, 2007
A phase II, double-blind, placebo-controlled, ascending-dose study of Eritoran (E5564), a lipid A antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypassElliott Bennett-Guerrero, Hilary P Grocott, Jerrold H Levy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 7, 2011
Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignanciesMonica Mita, Kevin R Kelly, Alain Mita, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 21, 2003
Extended in vivo pharmacodynamic activity of E5564 in normal volunteers with experimental endotoxemia [corrected]Melvyn Lynn, Y Nancy Wong, Janice L Wheeler, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 24, 2002
A novel class of endotoxin receptor agonists with simplified structure, toll-like receptor 4-dependent immunostimulatory action, and adjuvant activityLynn D Hawkins, Sally T Ishizaka, Pamela McGuinness, et al.
Nature|May 3, 2013
The TLR4 antagonist Eritoran protects mice from lethal influenza infectionKari Ann Shirey, Wendy Lai, Alison J Scott, et al.
JAMA|March 21, 2013
Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trialSteven M Opal, Pierre-Francois Laterre, Bruno Francois, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Anesthesia and Analgesia|January 24, 2007
A phase II, double-blind, placebo-controlled, ascending-dose study of Eritoran (E5564), a lipid A antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypassElliott Bennett-Guerrero, Hilary P Grocott, Jerrold H Levy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 7, 2011
Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignanciesMonica Mita, Kevin R Kelly, Alain Mita, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 21, 2003
Extended in vivo pharmacodynamic activity of E5564 in normal volunteers with experimental endotoxemia [corrected]Melvyn Lynn, Y Nancy Wong, Janice L Wheeler, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 24, 2002
A novel class of endotoxin receptor agonists with simplified structure, toll-like receptor 4-dependent immunostimulatory action, and adjuvant activityLynn D Hawkins, Sally T Ishizaka, Pamela McGuinness, et al.
Nature|May 3, 2013
The TLR4 antagonist Eritoran protects mice from lethal influenza infectionKari Ann Shirey, Wendy Lai, Alison J Scott, et al.
JAMA|March 21, 2013
Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trialSteven M Opal, Pierre-Francois Laterre, Bruno Francois, et al.
Pageof 2